Kevzara
E579611
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Kevzara canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6251175 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Kevzara Context triple: [Regeneron Pharmaceuticals, notableProduct, Kevzara]
-
A.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
B.
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
-
C.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
D.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Kevzara Target entity description: Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
-
A.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
B.
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
-
C.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
D.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic disease-modifying antirheumatic drug
ⓘ
monoclonal antibody ⓘ pharmaceutical drug ⓘ |
| actsOn | cytokine signaling pathway ⓘ |
| approvalYear | 2017 ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | L04AC14 ⓘ |
| belongsToRegimen | chronic long-term therapy for rheumatoid arthritis ⓘ |
| canBeUsedAs | monotherapy for rheumatoid arthritis ⓘ |
| canBeUsedWith | methotrexate ⓘ |
| contraindicatedIn | patients with active serious infections ⓘ |
| developedBy |
Regeneron Pharmaceuticals
NERFINISHED
ⓘ
Sanofi NERFINISHED ⓘ |
| dosageForm |
prefilled pen
ⓘ
prefilled syringe ⓘ |
| formulation | solution for injection ⓘ |
| hasActiveIngredient | sarilumab NERFINISHED ⓘ |
| hasBlackBoxWarning | risk of serious infections ⓘ |
| hasDrugClass |
immunosuppressive agent
ⓘ
interleukin-6 receptor antagonist ⓘ |
| hasGenericName | sarilumab NERFINISHED ⓘ |
| hasMolecularTarget | IL6R NERFINISHED ⓘ |
| hasTradeName | Kevzara NERFINISHED ⓘ |
| indicatedFor |
moderate rheumatoid arthritis in adults
ⓘ
severe rheumatoid arthritis in adults ⓘ |
| indicatedPopulation | adult patients ⓘ |
| inhibits | IL-6 receptor signaling ⓘ |
| isAdministered | every two weeks in many regimens ⓘ |
| isHumanized | true ⓘ |
| isMarketedIn |
European Union
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| legalStatus | prescription-only medicine ⓘ |
| mayCause |
elevated liver enzymes
ⓘ
injection site reactions ⓘ neutropenia ⓘ |
| mechanismOfAction | blocks binding of IL-6 to its receptor ⓘ |
| monoclonalAntibodyType | human monoclonal antibody ⓘ |
| reduces |
inflammation associated with rheumatoid arthritis
ⓘ
joint pain ⓘ joint swelling ⓘ |
| regulates | immune response ⓘ |
| requiresMonitoringOf |
lipid profile
ⓘ
liver function tests ⓘ neutrophil counts ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| targets | interleukin-6 receptor ⓘ |
| treats | rheumatoid arthritis ⓘ |
| usedAs | second-line therapy after inadequate response to other DMARDs ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Kevzara Description of subject: Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.